IIT Bhubaneswar Transfers Novel TB Vaccine Technology to TechInvention
Bhubaneswar, India – In a significant advancement in the fight against tuberculosis (TB), the Indian Institute of Technology (IIT) Bhubaneswar, in collaboration with the Institute of Life Sciences (ILS) and the National Research Development Corporation (NRDC), has officially transferred a novel TB vaccine technology to TechInvention Lifecare Ltd. This agreement was formalized through a quadripartite license agreement (QLA) signed on November 24, 2025.
Overview of the Vaccine Technology
The vaccine technology in question is known as the ‘HSP Subunit Vaccine in Adjuvant (DDA) Against Mycobacterium tuberculosis’. This innovative vaccine candidate was developed through collaborative research efforts led by Ashis Biswas from IIT Bhubaneswar and Sunil Kumar Raghav from ILS, Bhubaneswar. The NRDC played a crucial role in identifying and evaluating the technology, facilitating the licensing process to ensure its advancement towards commercialization.
Importance of the Technology Transfer
The transfer of this vaccine technology to TechInvention Lifecare Ltd is a pivotal step in translating indigenous research into a viable public health solution. Tuberculosis remains one of the deadliest infectious diseases globally, with the World Health Organization (WHO) reporting that TB claimed 1.23 million lives in 2024 alone. The urgency to combat this epidemic is underscored by the United Nations Sustainable Development Goals (SDGs), which aim to end the TB epidemic by 2030.
Limitations of Existing Vaccines
Currently, the world predominantly relies on the Bacillus Calmette Guerin (BCG) vaccine, which was developed over a century ago. While the BCG vaccine offers some protection, particularly to infants, it is largely ineffective in preventing pulmonary TB in adolescents and adults. This highlights a critical unmet need for more effective vaccines against TB.
Features of the HSP Subunit Vaccine
The HSP Subunit Vaccine is designed to address these limitations by triggering strong humoral and cell-mediated immune responses. It aims to enhance the protective efficacy of the existing BCG vaccine, thereby providing a more robust defense against TB.
Collaboration and Future Prospects
This partnership between IIT Bhubaneswar, ILS, NRDC, and TechInvention Lifecare Ltd not only ensures the efficient advancement of the vaccine candidate from research to product development and validation but also emphasizes the significance of indigenous, research-driven healthcare innovations. Such collaborations are essential for strengthening India’s mission to eliminate tuberculosis and improving global health outcomes.
Conclusion
The transfer of this novel TB vaccine technology marks a promising development in the ongoing battle against tuberculosis. With the combined efforts of premier research institutions and industry partners, there is hope for a future where effective TB vaccines are accessible, ultimately contributing to the global goal of eradicating this deadly disease.
Note: This article is based on information provided by PTI and has not been edited by The Week.
